About The Study: The findings of this study suggest that metabolic bariatric surgery was associated with more weight loss at lower ongoing costs compared with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in class II and III obesity. Further study is needed to determine if metabolic bariatric surgery should still be considered the last resort in treating obesity.
Corresponding Author: To contact the corresponding author, George M. Eid, MD, email george.eid@ahn.org .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamasurg.2025.3590)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2025.3590?guestAccessKey=f92dccf3-f8e2-4789-95d7-61dd539ed7e0&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091725
JAMA Surgery